Logo image of DBTX

DECIBEL THERAPEUTICS INC (DBTX) Stock Fundamental Analysis

NASDAQ:DBTX - Nasdaq - US24343R1068 - Common Stock - Currency: USD

4.91  -0.04 (-0.81%)

After market: 4.91 0 (0%)

Fundamental Rating

2

DBTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. Both the profitability and financial health of DBTX have multiple concerns. DBTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year DBTX has reported negative net income.
DBTX had a negative operating cash flow in the past year.
DBTX had negative earnings in 4 of the past 5 years.
DBTX had a negative operating cash flow in each of the past 5 years.
DBTX Yearly Net Income VS EBIT VS OCF VS FCFDBTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 0 -20M -40M -60M

1.2 Ratios

DBTX has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DBTX Yearly ROA, ROE, ROICDBTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 0 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DBTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DBTX Yearly Profit, Operating, Gross MarginsDBTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022

More info and screens

3

2. Health

2.1 Basic Checks

DBTX has about the same amout of shares outstanding than it did 1 year ago.
The debt/assets ratio for DBTX is higher compared to a year ago.
DBTX Yearly Shares OutstandingDBTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 5M 10M 15M 20M
DBTX Yearly Total Debt VS Total AssetsDBTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -4.40, we must say that DBTX is in the distress zone and has some risk of bankruptcy.
DBTX's Altman-Z score of -4.40 is on the low side compared to the rest of the industry. DBTX is outperformed by 64.40% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that DBTX is not too dependend on debt financing.
DBTX has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.4
ROIC/WACCN/A
WACCN/A
DBTX Yearly LT Debt VS Equity VS FCFDBTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 3.03 indicates that DBTX has no problem at all paying its short term obligations.
With a Current ratio value of 3.03, DBTX is not doing good in the industry: 70.53% of the companies in the same industry are doing better.
DBTX has a Quick Ratio of 3.03. This indicates that DBTX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.03, DBTX is not doing good in the industry: 68.87% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.03
Quick Ratio 3.03
DBTX Yearly Current Assets VS Current LiabilitesDBTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for DBTX have decreased by -9.05% in the last year.
EPS 1Y (TTM)-9.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

DBTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.33% yearly.
Based on estimates for the next years, DBTX will show a very strong growth in Revenue. The Revenue will grow by 83.11% on average per year.
EPS Next Y-15%
EPS Next 2Y-4.16%
EPS Next 3Y9.38%
EPS Next 5Y12.33%
Revenue Next Year-100%
Revenue Next 2Y11.8%
Revenue Next 3Y-25.99%
Revenue Next 5Y83.11%

3.3 Evolution

DBTX Yearly Revenue VS EstimatesDBTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2024 2026 2027 2028 100M 200M 300M
DBTX Yearly EPS VS EstimatesDBTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DBTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DBTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DBTX Price Earnings VS Forward Price EarningsDBTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DBTX Per share dataDBTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.16%
EPS Next 3Y9.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DBTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DECIBEL THERAPEUTICS INC

NASDAQ:DBTX (9/22/2023, 8:00:01 PM)

After market: 4.91 0 (0%)

4.91

-0.04 (-0.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2023-08-11/bmo
Earnings (Next)11-07 2023-11-07/amc
Inst Owners0.16%
Inst Owner Change0%
Ins Owners9.14%
Ins Owner Change0%
Market Cap123.39M
Analysts78
Price Target7.78 (58.45%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.19%
Min EPS beat(2)-30.24%
Max EPS beat(2)13.85%
EPS beat(4)2
Avg EPS beat(4)-15.58%
Min EPS beat(4)-54.48%
Max EPS beat(4)13.85%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-47.05%
PT rev (3m)-42.09%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-29.92%
EPS NY rev (1m)-32.49%
EPS NY rev (3m)-11.01%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.31
P/tB 2.31
EV/EBITDA N/A
EPS(TTM)-2.53
EYN/A
EPS(NY)-2.72
Fwd EYN/A
FCF(TTM)-1.96
FCFYN/A
OCF(TTM)-1.94
OCFYN/A
SpS0
BVpS2.12
TBVpS2.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.53%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.03
Quick Ratio 3.03
Altman-Z -4.4
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)33.62%
Cap/Depr(5y)45.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.35%
EPS Next Y-15%
EPS Next 2Y-4.16%
EPS Next 3Y9.38%
EPS Next 5Y12.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y11.8%
Revenue Next 3Y-25.99%
Revenue Next 5Y83.11%
EBIT growth 1Y-12.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.89%
EBIT Next 3Y-15.53%
EBIT Next 5Y4.21%
FCF growth 1Y-40.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.31%
OCF growth 3YN/A
OCF growth 5YN/A